Publication

Serum free thiols in chronic heart failure

Koning, A. M., Meijers, W. C., Pasch, A., Leuvenink, H. G. D., Frenay, A-R. S., Dekker, M. M., Feelisch, M., de Boer, R. A. & Goor, van, H., Sep-2016, In : Pharmacological research. 111, p. 452-458 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Koning, A. M., Meijers, W. C., Pasch, A., Leuvenink, H. G. D., Frenay, A-R. S., Dekker, M. M., ... Goor, van, H. (2016). Serum free thiols in chronic heart failure. Pharmacological research, 111, 452-458. https://doi.org/10.1016/j.phrs.2016.06.027

Author

Koning, Anne M. ; Meijers, Wouter C. ; Pasch, Andreas ; Leuvenink, Henri G. D. ; Frenay, Anne-Roos S. ; Dekker, Marinda M. ; Feelisch, Martin ; de Boer, Rudolf A. ; Goor, van, Harry. / Serum free thiols in chronic heart failure. In: Pharmacological research. 2016 ; Vol. 111. pp. 452-458.

Harvard

Koning, AM, Meijers, WC, Pasch, A, Leuvenink, HGD, Frenay, A-RS, Dekker, MM, Feelisch, M, de Boer, RA & Goor, van, H 2016, 'Serum free thiols in chronic heart failure', Pharmacological research, vol. 111, pp. 452-458. https://doi.org/10.1016/j.phrs.2016.06.027

Standard

Serum free thiols in chronic heart failure. / Koning, Anne M.; Meijers, Wouter C.; Pasch, Andreas; Leuvenink, Henri G. D.; Frenay, Anne-Roos S.; Dekker, Marinda M.; Feelisch, Martin; de Boer, Rudolf A.; Goor, van, Harry.

In: Pharmacological research, Vol. 111, 09.2016, p. 452-458.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Koning AM, Meijers WC, Pasch A, Leuvenink HGD, Frenay A-RS, Dekker MM et al. Serum free thiols in chronic heart failure. Pharmacological research. 2016 Sep;111:452-458. https://doi.org/10.1016/j.phrs.2016.06.027


BibTeX

@article{161561041a3f4215932138b06e8294f3,
title = "Serum free thiols in chronic heart failure",
abstract = "Oxidative stress is a key element of the pathophysiology of heart failure (HF). As free thiols are readily oxidized by reactive oxygen and sulfur species, their circulating level may directly reflect the systemic redox status. This study addresses the role of serum free thiols in chronic HF, which is of particular interest as free thiols are amenable to therapeutic modulation and thus are a potential target for therapy.Free thiols were measured in serum of 101 previously characterized stable chronic HF patients (93{\%} male, age 63.7 +/- 10.0 y, left ventricular ejection fraction 34.6 +/- 8.2{\%}), adjusted for total serum protein, and subsequently analysed for associations with clinical and outcome parameters.The mean serum free thiol concentration was 3.6 +/- 0.5 mu M/g protein. Patients with above-average levels were younger, had better renal function, lower levels of NT-proBNP and PTH, and higher levels of cholesterol. Furthermore, above-average levels were associated with favourable disease outcome, i.e. a decreased rehospitalisation rate and increased patient survival (HR 0.27 (95{\%} CI 0.11-0.62), P = 0.002) independent of associated clinical parameters, age and PTH. After adjustment for cholesterol or established prognostic factors in HF, eGFR and NT-proBNP the association was no longer significant, suggesting involvement of these variables in a common pathophysiological pathway.This exploratory study demonstrates favourable associations of serum free thiols with markers of HF severity and prognosis as well as disease outcome, which should be further investigated in larger prospective studies. Restoring redox status by therapeutic modulation of free thiols may be a promising strategy to improve disease outcome in CHF. (C) 2016 Elsevier Ltd. All rights reserved.",
keywords = "Chronic heart failure, Thiols, Redox status, Oxidative stress, Rehospitalisation, Survival, OXIDATIVE STRESS, HUMAN PLASMA, EUROPEAN-SOCIETY, FREE-RADICALS, REDOX STATUS, TASK-FORCE, DISEASE, ASSOCIATION, ANTIOXIDANT, DIAGNOSIS",
author = "Koning, {Anne M.} and Meijers, {Wouter C.} and Andreas Pasch and Leuvenink, {Henri G. D.} and Frenay, {Anne-Roos S.} and Dekker, {Marinda M.} and Martin Feelisch and {de Boer}, {Rudolf A.} and {Goor, van}, Harry",
note = "Copyright {\circledC} 2016 Elsevier Ltd. All rights reserved.",
year = "2016",
month = "9",
doi = "10.1016/j.phrs.2016.06.027",
language = "English",
volume = "111",
pages = "452--458",
journal = "Pharmacological research",
issn = "1043-6618",
publisher = "ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD",

}

RIS

TY - JOUR

T1 - Serum free thiols in chronic heart failure

AU - Koning, Anne M.

AU - Meijers, Wouter C.

AU - Pasch, Andreas

AU - Leuvenink, Henri G. D.

AU - Frenay, Anne-Roos S.

AU - Dekker, Marinda M.

AU - Feelisch, Martin

AU - de Boer, Rudolf A.

AU - Goor, van, Harry

N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.

PY - 2016/9

Y1 - 2016/9

N2 - Oxidative stress is a key element of the pathophysiology of heart failure (HF). As free thiols are readily oxidized by reactive oxygen and sulfur species, their circulating level may directly reflect the systemic redox status. This study addresses the role of serum free thiols in chronic HF, which is of particular interest as free thiols are amenable to therapeutic modulation and thus are a potential target for therapy.Free thiols were measured in serum of 101 previously characterized stable chronic HF patients (93% male, age 63.7 +/- 10.0 y, left ventricular ejection fraction 34.6 +/- 8.2%), adjusted for total serum protein, and subsequently analysed for associations with clinical and outcome parameters.The mean serum free thiol concentration was 3.6 +/- 0.5 mu M/g protein. Patients with above-average levels were younger, had better renal function, lower levels of NT-proBNP and PTH, and higher levels of cholesterol. Furthermore, above-average levels were associated with favourable disease outcome, i.e. a decreased rehospitalisation rate and increased patient survival (HR 0.27 (95% CI 0.11-0.62), P = 0.002) independent of associated clinical parameters, age and PTH. After adjustment for cholesterol or established prognostic factors in HF, eGFR and NT-proBNP the association was no longer significant, suggesting involvement of these variables in a common pathophysiological pathway.This exploratory study demonstrates favourable associations of serum free thiols with markers of HF severity and prognosis as well as disease outcome, which should be further investigated in larger prospective studies. Restoring redox status by therapeutic modulation of free thiols may be a promising strategy to improve disease outcome in CHF. (C) 2016 Elsevier Ltd. All rights reserved.

AB - Oxidative stress is a key element of the pathophysiology of heart failure (HF). As free thiols are readily oxidized by reactive oxygen and sulfur species, their circulating level may directly reflect the systemic redox status. This study addresses the role of serum free thiols in chronic HF, which is of particular interest as free thiols are amenable to therapeutic modulation and thus are a potential target for therapy.Free thiols were measured in serum of 101 previously characterized stable chronic HF patients (93% male, age 63.7 +/- 10.0 y, left ventricular ejection fraction 34.6 +/- 8.2%), adjusted for total serum protein, and subsequently analysed for associations with clinical and outcome parameters.The mean serum free thiol concentration was 3.6 +/- 0.5 mu M/g protein. Patients with above-average levels were younger, had better renal function, lower levels of NT-proBNP and PTH, and higher levels of cholesterol. Furthermore, above-average levels were associated with favourable disease outcome, i.e. a decreased rehospitalisation rate and increased patient survival (HR 0.27 (95% CI 0.11-0.62), P = 0.002) independent of associated clinical parameters, age and PTH. After adjustment for cholesterol or established prognostic factors in HF, eGFR and NT-proBNP the association was no longer significant, suggesting involvement of these variables in a common pathophysiological pathway.This exploratory study demonstrates favourable associations of serum free thiols with markers of HF severity and prognosis as well as disease outcome, which should be further investigated in larger prospective studies. Restoring redox status by therapeutic modulation of free thiols may be a promising strategy to improve disease outcome in CHF. (C) 2016 Elsevier Ltd. All rights reserved.

KW - Chronic heart failure

KW - Thiols

KW - Redox status

KW - Oxidative stress

KW - Rehospitalisation

KW - Survival

KW - OXIDATIVE STRESS

KW - HUMAN PLASMA

KW - EUROPEAN-SOCIETY

KW - FREE-RADICALS

KW - REDOX STATUS

KW - TASK-FORCE

KW - DISEASE

KW - ASSOCIATION

KW - ANTIOXIDANT

KW - DIAGNOSIS

U2 - 10.1016/j.phrs.2016.06.027

DO - 10.1016/j.phrs.2016.06.027

M3 - Article

VL - 111

SP - 452

EP - 458

JO - Pharmacological research

JF - Pharmacological research

SN - 1043-6618

ER -

ID: 34535153